{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:14:34Z","timestamp":1790306074699,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jtho.2018.07.094","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T08:23:59Z","timestamp":1534407839000},"page":"1940-1948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Olumide B.","family":"Gbolahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan F.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Salter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Yiannoutsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Gabriella","family":"Chiorean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sr.","given":"Patrick. J.","family":"Loehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.07.094_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9610(78)90199-X","article-title":"Thymoma: a ten year review","volume":"136","author":"Gerein","year":"1978","journal-title":"Am J Surg"},{"key":"10.1016\/j.jtho.2018.07.094_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0003-4975(10)62751-8","article-title":"Primary anterior mediastinal tumors in children and adults","volume":"42","author":"Mullen","year":"1986","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2018.07.094_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1592\/phco.26.5.641","article-title":"Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy","volume":"26","author":"Villela","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtho.2018.07.094_bib5","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2018.07.094_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2307\/2531294","article-title":"Confidence limits for probability of response in multistage phase II clinical trials","volume":"41","author":"Atkinson","year":"1985","journal-title":"Biometrics"},{"key":"10.1016\/j.jtho.2018.07.094_bib11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","article-title":"A\u00a0phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours","volume":"95","author":"Nakagawa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jtho.2018.07.094_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2015.425","article-title":"A\u00a0large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas","volume":"114","author":"Radovich","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2018.07.094_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jtcvs.2009.03.033","article-title":"Comparison of patterns of relapse in thymic carcinoma and thymoma","volume":"138","author":"Huang","year":"2009","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.07.094_bib17","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1158\/1078-0432.CCR-17-0066","article-title":"Genomic analysis of thymic epithelial tumors identifies novel subtypes associated with distinct clinical features","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.07.094_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2018.07.094_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib20","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib23","unstructured":"National Comprehensive Cancer Network. Thymomas and thymic carcinomas. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thymic.pdf. Accessed December 23, 2017\u00a02017."},{"key":"10.1016\/j.jtho.2018.07.094_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2018.07.094_bib25","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/JTO.0b013e3181b9e608","article-title":"Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB\/IV non-small cell lung cancer: review of results from an open-label randomized phase II study","volume":"4","author":"Kubota","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cncr.22208","article-title":"Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase","volume":"107","author":"Ceppi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib27","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","article-title":"Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma","volume":"7","author":"Christoph","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib28","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/JTO.0b013e318287c224","article-title":"Reduced folate carrier and folylpolyglutamate synthetase, but\u00a0not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma","volume":"8","author":"Mairinger","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JTO.0b013e318283da3e","article-title":"Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma","volume":"8","author":"Lustgarten","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.lungcan.2011.04.001","article-title":"Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors","volume":"74","author":"Kaira","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib31","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtho.2018.07.094_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtho.2018.07.094_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtho.2018.07.094_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"Palmieri","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtho.2018.07.094_bib37","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib38","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.094_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","article-title":"A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies","volume":"89","author":"Gubens","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.07.094_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.7580","article-title":"Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM)","volume":"33","author":"Wakelee","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtho.2018.07.094_bib41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418309316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418309316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:37:42Z","timestamp":1761561462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418309316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1556086418309316"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.07.094","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.07.094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}